ARCHIMED, a global investment firm focused on sustainable healthcare, has announced the sale of DIESSE, an Italian producer of specialty in-vitro diagnostics (IVD) solutions, to private equity firm Fremman Capital.
French REIT Praemia REIM (formerly Primonial REIM) is reportedly considering listing a new specialist healthcare real estate investment trust (REIT) in Singapore.
The sale of US-based healthcare BPO firm GeBBS Healthcare Solutions has entered its final stage, with Asian and European funds competing for acquisition. Hong Kong’s Hillhouse Investment has emerged as the frontrunner and is reported to have offered approximately USD $870 million for a 100% stake, slightly ahead of Sweden’s EQT Partners' bid of $855-860 […]
Alicante-based Sha Wellness Clinic last week announced a collaborative venture with Abu Dhabi's IMKAN to develop ‘Sha Residences Emirates’, a luxury wellness residential complex located on the private island of AlJurf between Abu Dhabi and Dubai.
In a significant development for the Northern Irish health tech industry, Belfast-based Neurovalens has obtained medical device clearance from the US Food & Drug Administration (FDA) for their Modius Stress device aimed at treating anxiety.
Pan-European listed French nursing home group Clariane has successfully exited the UK with the sale of its Berkley Care subsidiary. The group has also made progress on the sale of its Belgian and Dutch branches, but has not yet secured a buyer for these.
Listed Malaysian hospital group KPJ Healthcare is selling non-core assets it holds outside of Malaysia to focus on its Malaysian hospital segment. It has already fully exited Indonesia and plans to fully exit Australia within the next two years, and may also exit Bangladesh. It still has a hospital in Thailand which it has no plans to sell, as it is focused on medical tourism - a key part of the company's strategy going forward. The company reported strong results for 2023, with revenue up 19% and core net profit up 61%.
Global investment banking firm Goldman Sachs has closed one of the largest first-time private life sciences growth funds. Its West Street Life Sciences I raised "$650 million in equity commitments from a global, diverse group of institutional, strategic and high net worth investors and meaningful commitment from Goldman Sachs employees" according to the bank.
New highly effective weight loss drugs could create a market worth more than $100bn in annual revenue by 2030. Whilst the majority of this value will be captured by the pharma industry, HBI hears there will be a significant role for specialised clinical providers who can deliver these medicines alongside behavioural and lifestyle changes.
Healthcare Business International users cookies to improve the functionality, performance, and effectiveness of our communications. Detailed information on the use of cookies is provided in our Cookies Policy. By continuing to use this site, or by clicking "I agree" you consent to the use of cookies.
